Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05286138
Recruiting Observational

STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY

NCT05286138 · tracked via the Priya Life Science Italy tracker
Sponsor
Società Italiana Talassemie ed Emoglobinopatie
Phase
Observational
Started
2022-02-01
Last updated
2022-04-01

Condition(s) studied

Malignacy, Hemoglobinopathie

Study summary

The Trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are more frequent in patients with hemoglobinopathies. Still, in relation to tumor pathology, the study will evaluate any differences between the different types of hemoglobinopathy and will investigate the association between the appearance of neoplasms and risk factors such as age, sex, iron accumulation markers, history of bone marrow transplant, and others.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Transfusion-dependent or independent beta-thalassemia, hemoglobin H disease, sickle cell anemia and microdrepanocytosis * Current or previous malignant tumor pathology * Availability of medical history including the most relevant clinical and instrumental data before the onset of cancer Exclusion Criteria: * \- Other haematological diseases other than hemoglobinopathies * Absence of neoplastic events in the clinical history * Non-availability of relevant clinical and instrumental data

Primary outcome measure(s)

  • outcome 1 — ENROLLMENT STUDY
    Evaluate the number of patients with hemoglobinopathy followed at Italian centers that have developed neoplastic events in the last decades
  • outcome 2 — enrollment study
    Evaluate which neoplasms are most associated with hemoglobinopathies
  • outcome 3 — enrollment study
    Identify any risk factors for the onset of neoplasms in patients with hemoglobinopathies.

Trial sites (1)

FacilityCityRegionStatus
Azienda Ospedaliera Universitaria Di Cagliari Cagliari Italy Recruiting

More Società Italiana Talassemie ed Emoglobinopatie trials in Italy

Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination Patients With Thalassemic and Falcemic Syndromes Active, not recruiting
Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05286138 on ClinicalTrials.gov ↗ ← All trials in Italy